CGM is superior to capillary blood glucose monitoring for improving glycaemic patterns among insulin-treated patients with type 1 diabetes and type 2 diabetes, especially those with out-of-range glucose levels. This evidence concerns the gene INS and type 2 diabetes mellitus.